Phase II Study of Vinorelbine in Patients With Malignant Pleural Mesothelioma

Abstract

Vinorelbine shows promise in the palliation of patients with malignant pleural mesothelioma. The relatively low toxicity of the drug suggests that trials of vinorelbine in combination with other agents should be feasible.